Weiss Michael S's Form 4 filing
TG Therapeutics, Inc. (TGTX) · filed Jan 7, 2022
- Accession no.
- 0001104659-22-002355
- Filed
- Jan 7, 2022
- Trade date
- Dec 15, 2021-Jan 5, 2022
- Filing delay
- 23 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.28M. It was filed 23 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Weiss Michael SCIK 0001038977 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2021 | COMMON STOCK | GGiftDisposed | −3,000 | $0.00 | $0 | 14,145,852 | Direct | |
| Dec 16, 2021 | COMMON STOCK | GGiftDisposed | −700,000 | $0.00 | $0 | 13,445,852 | Direct | |
| Dec 16, 2021 | COMMON STOCK | GGiftDisposed | −9,000 | $0.00 | $0 | 13,436,852 | Direct | |
| Dec 29, 2021 | COMMON STOCK | AGrant or awardAcquired | +56,394 | $0.00 | $0 | 13,493,246 | Direct | |
| Jan 4, 2022 | COMMON STOCK | SSaleDisposed | −37,549 | $19.20 | −$720,940.8 | 13,455,697 | Direct | |
| Jan 5, 2022 | COMMON STOCK | SSaleDisposed | −30,671 | $18.31 | −$561,586.01 | 10,988,021 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.